home / stock / vrna / vrna news

VRNA News and Press, Verona Pharma plc From 10/20/23

Stock Information
Company Name: Verona Pharma plc
Stock Symbol: VRNA
Market: NASDAQ
Website: veronapharma.com
Menu
VRNA VRNA Quote VRNA Short VRNA News VRNA Articles VRNA Message Board
Get VRNA Alerts

News, Short Squeeze, Breakout and More Instantly...
VRNA - GPRO, WISH and BGFY are among after hour movers

2023-10-20 17:24:19 ET Gainers: Day One Biopharmaceuticals ( DAWN ) +6% . ContextLogic  ( WISH ) +5% . Vital Farms ( VITL ) +5% . Verona Pharma  ( VRNA ) +4% . GoPro ( GPRO ) +3% . Losers: IGM Biosciences ( IG...
VRNA - Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the thir...

VRNA - Verona Pharma to Host Investor Update on Commercialization Preparation for Ensifentrine on October 18, 2023

LONDON and RALEIGH, N.C., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces it will hold an Investor Update in New York City for investors and analysts on Wednesday, October 18, 2023, from 8:00 - 10:00 AM E...

VRNA - Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023

PDUFA Target Action Date of June 26, 2024 Pooled analysis and subgroup data further support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRN...
VRNA - Verona Pharma granted FDA review for COPD therapy

2023-09-11 09:18:57 ET More on Verona Seeking Alpha’s Quant Rating on Verona Pharma Historical earnings data for Verona Pharma Financial information for Verona Pharma Verona Pharma: De-Risked COPD Biotech Play, Approval Likely Coming Soon Veron...

VRNA - Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD

PDUFA Target Action Date of June 26, 2024 Ensifentrine, if approved, is expected to be the first novel mechanism available for the maintenance treatment of COPD in more than a decade LONDON and RALEIGH, N.C., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) ( ...

VRNA - Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023

LONDON and RALEIGH, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces an oral presentation on an additional analysis from its successful Phase 3 ENHANCE-1 study with ensifentrine for the treatment of...
VRNA - Verona Pharma: De-Risked COPD Biotech Play, Approval Likely Coming Soon

2023-09-04 23:45:50 ET Summary Verona Pharma has submitted a New Drug Application (NDA) for ensifentrine, a potential treatment for COPD, to the FDA. The FDA has a 60-day window to accept or reject the filing, with a potential approval date as early as January 2024. Verona Pha...

VRNA - Verona Pharma: Financial Health And COPD Market Impact 2024

2023-08-24 16:05:17 ET Summary Verona Pharma is seeking FDA approval for its COPD treatment, ensifentrine, in 2024. The company has a strong financial position with substantial cash reserves and no immediate need for additional financing. Verona Pharma's ensifentrine has the p...

VRNA - Verona Pharma: Targeting The Large COPD Market

2023-08-08 16:44:55 ET Summary Verona Pharma plc is a London-based biopharma company focused on developing respiratory disease treatments. The company recently submitted a NDA for its primary drug candidate that is targeting the large and growing COPD market. The stock has ris...
Previous 10 Next 10